Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma

23 Apr 2010

Abstract excerpt

OBJECTIVE: HDAC inhibitors (HDI) are anti-neoplastic drugs with preliminary successful clinical applications in Hodgkin's lymphoma (HL). Systematic investigations of HDAC expression in HL, based on histology and immunohistochemistry are yet rare. RESEARCH DESIGN/METHODS: We investigated the expression of HDAC1, 2 and 3 in 283 HL on tissue microarrays. MAIN OUTCOME MEASURES: Expression of HDAC isoforms was scored...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Lymphoma Diagnosis and Treatment
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20415600
DOI: 10.1517/14728221003796609

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphomaPMID 20415600Read ↗

Comprehensive analysis of HDAC7 expression and its prognostic value in diffuse large B cell lymphomaSemantic proximity Read ↗

HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significanceSemantic proximity Read ↗

Targeting HDACs for diffuse large B-cell lymphoma therapySemantic proximity Read ↗

Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCCSemantic proximity Read ↗

Targeting class I histone deacetylases in cancer therapySemantic proximity Read ↗

Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.Semantic proximity Read ↗

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALLSemantic proximity Read ↗

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative DiseaseSemantic proximity Read ↗

Targeting histone deacetyalses in the treatment of B- and T-cell malignanciesSemantic proximity Read ↗

Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV‐independent major determinant of microenvironment composition in classic Hodgkin lymphomaSemantic proximity Read ↗

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphomaSemantic proximity Read ↗

[Histone deacetylase inhibitors: highlight on epigenetic regulation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.